Evidence map›Paper›PMID 39920279›Full record

ArticleScientific reports2025

Adli A Selim, Tamer M Sakr, Basma M Essa, Galal H Sayed, Kurls E Anwer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Adli A SelimLabelled Compounds Department, Egyptian Atomic Energy Authority (EAEA), Cairo, 13759, Egypt. adli_a_selim@yahoo.com.ORCID 0000-0001-7095-5978
Tamer M SakrRadioactive Isotopes and Generators Department, Egyptian Atomic Energy Authority (EAEA), Cairo, 13759, Egypt.
Basma M EssaRadioactive Isotopes and Generators Department, Egyptian Atomic Energy Authority (EAEA), Cairo, 13759, Egypt.
Galal H SayedHeterocyclic Synthesis Lab., Chemistry Department, Faculty of Science, Ain Shams University, Abbassia, Cairo, 11566, Egypt.
Kurls E AnwerHeterocyclic Synthesis Lab., Chemistry Department, Faculty of Science, Ain Shams University, Abbassia, Cairo, 11566, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sulfonamide derivatives are a significant class of medicinal compounds. Gold nanoparticles (AuNPs) offer precise cancer treatment through targeted delivery, boasting high drug-loading capacity and low toxicity. This study aimed to develop and evaluate 99mTc-labeled benzenesulfonamide derivative-entrapped gold citrate nanoparticles as a tumor-targeting agent. A novel benzenesulfonamide derivative bearing a pyridine moiety was synthesized. Compound 3 (4-((3-cyano-4-(2,4-dichlorophenyl)-6-phenylpyridin-2-yl)amino)-N-(diaminomethylene)benzenesulfonamide) exhibited remarkable anti-cancer activity against MCF-7 cells. The chemical reduction method was employed to create compound 3-citrate-AuNPs. A comprehensive examination of the synthesized nano-platform was conducted, including zeta potential, size analysis, radiochemical yield, and in-vivo biodistribution in tumor-bearing mice. The nano-platform was successfully produced with good stability, optimal particle size (9 nm diameter for AuNPs), and high radiochemical purity for [

Indexed as

Antineoplastic AgentsGoldMetal NanoparticlesSulfonamidesTechnetiumAnimalsFemaleHumansMCF-7 CellsMiceTissue DistributionAntineoplastic AgentsGoldSulfonamidesTechnetium99mTc-radiolabelingBenzenesulfonamideCitrate-AuNPsPyridine moietyTumour targeting

Identifiers

PMID39920279
PMCPMC11806107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.